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Stem cell technology has a number potential uses when it comes to the eye, particularly 
disease and developmental modelling, and as potential therapeutic source. A variety of 
protocols have been developed that facilitate the generation of the different cell types 
found within the eye as well as those that produce a facsimile of the developing eye in 
vitro. This chapter introduces the importance of the Retinal Pigment Epithelium (RPE) in 
maintaining visual function. We then focus on methods developed by our group to 
produce RPE from patient skin samples using human induced pluripotent stem cell 
technology.  
 







The Retinal pigment epithelium (RPE) is the monolayer of epithelium found at the back 
of the eye, behind the retina. The RPE performs a support and maintenance	  role for the 
retina and is involved in many processes crucial to the health of the overlying 
photoreceptive cells (Strauss, 2005). The transport of nutrients, water and ions from the 
blood supply to photoreceptor cells is regulated by the RPE. The RPE is involved in the 
phagocytosis of photoreceptor outer segments (POS) discarded daily by the retina. The 
RPE is responsible for binding (mediated by Integrins and CD36 and 81), engulfing 
(FAK and MERTK) and breaking down the shed POS. The RPE also plays an important 
role in the visual cycle and produces various proteins, including RPE65 and RLBP1, 
which play crucial roles in retinoid recycling (see Tables 1A and 1B). The RPE is a 
highly pigmented monolayer, with each cell containing many melanosomes	   that aid 
vision by absorbing any stray light inside the eye. Within the monolayer, individual RPE 
cells are tightly packed together to give a ‘cobblestone’-like morphology. The formation 
of tight junctions between cells is crucial for the role of the RPE as a component of the 
blood:retina barrier. The development of tight junctions is also crucial for establishing 
the polarity of the RPE, which results in the expression of ion pumps/channels such as 
Na+/K+ ATPase and Bestrophin at the apical and basolateral surface respectively and 
the polarized secretion of growth factors, such as Pigment epithelium-derived growth 




The RPE is vital for the maintenance of vision, therefore the deterioration of, or 
deficiencies in the functional performance of the RPE can result in various forms of 
blindness. RPE-specific rare inherited genetic disorders (Table 1) and a number of 
degenerative conditions, such as age-related macular degeneration (AMD) arise when 
the RPE is lost or dysfunctional. AMD is the leading cause of sight loss in the developed 
world; there are over half a million people diagnosed with late-stage AMD in the UK, 
and around half of these are registered as visually impaired. Clinically, there are two 
forms of AMD, the slowly progressing non-exudative form, known as dry AMD, and 
rapidly developing exudative or “wet” AMD, which results from the infiltration of new, 
leaky blood vessels through the RPE barrier. A number of pharmaceutical products are 
available to treat wet AMD, namely Anti-VEGF drugs e.g. Ranibizumab (Lucentis) and 
Bevacizumab (Avastin). New drugs in the anti-VEGF class are being developed but 
these treatments tend only to arrest decline in vision rather than inducing any significant 
improvement. Anti-VEGFs are ineffective in some patients with wet AMD and are of no 
benefit to the patient population with dry AMD. Over recent years, focus has turned to 
using a cell therapy for the treatment of AMD, however, whilst it is possible to utilise 
RPE from an extra-macula area of a patients own eye, it is technically quite difficult to 
do so, and the cells/tissue yielded are fragile and limited in amount. Human primary 
RPE is also difficult to obtain due to reliance on post-mortem tissues. These sources 
are inconsistent and limited, which makes planning studies for transplantation 
therapeutics very difficult. This makes non-donor derived RPE a highly desirable 
research and clinical resource for cell transplantation.  
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With the advent of the regenerative medicine era, much effort has been directed to 
using stem cells as a potential source to generate new RPE (Carr et al. 2013). These 
cell therapies have the potential to replace lost or damaged cells and therefore improve 
the recipients’ visual acuity. Human embryonic stem cells (hESC) have been used to 
generate RPE for treatment of AMD and Stargardt’s Macular dystrophy in on-going 
clinical trials (Schwartz et al. 2012; Schwartz et al. 2014), however, due to the origin of 
these cells, there may be concerns with immune rejection.  Induced pluripotent stem 
cells (iPSC) offer an alternative source of tissue for transplantation therapies. Somatic 
cells isolated patient tissues, such as skin and blood, can be reprogrammed into iPSCs, 
which can then be used to generate any tissue within the body (Takahashi et al. 2007; 
Yu et al. 2007). Development of new methods to reprogram cells, e.g. using episomal 
vectors, rather than the original retroviral constructs, make generation of iPSC safer for 
use in humans (Okita et al. 2011; Goh et al. 2014). Many groups have described 
methods to differentiate RPE from iPSC, these range from protocols describing 
spontaneous differentiation (Carr et al. 2009A) differentiation via embryoid body/neural 
differentiation (Meyer et al. 2009) and directed differentiation (Westenskow et al. 2012). 
Studies have shown that these iPSC-derived RPE are morphologically similar to human 
RPE, perform many of the functions required to maintain the health of retinal cells (Carr 
et al. 2009A; Meyer et al. 2011; Vaajasaari et al. 2011; Kokkinaki et al. 2011; 
Westenskow et al. 2012) and do not form teratomas upon transplantation in the 
subretinal space (Kanemura et al. 2014). The possibility of producing stem cells from a 
patient’s own tissue, and differentiating these cells into an autologous source of 
functional RPE, may alleviate rejection issues associated with HESC-derived tissues. 
6	  
	  
The generation of RPE from induced pluripotent cells also offers other areas of 
possibility for the novel treatment of diseases. Genetic disorders affecting the RPE may 
be rare in terms of overall incidence, but still affect thousands of people worldwide. In 
many of these conditions there is no sufficiently analogous animal model available. 
Using iPSCs derived from patients to generate the required tissue in the laboratory 
presents an opportunity to study these conditions at the cellular and molecular level 
Furthermore, the generation of RPE from a patients own cells provides a unique 
opportunity to investigate new medicinal products, using the patients own cells as a 
model platform to screen for novel therapeutics in human diseased cells (Meyer et al. 
2011; Schwarz et al. 2015). Additionally, the generation of RPE from pluripotent stem 







2.1 Solutions and chemicals 
1. 70% alcohol solution. 
2. Fibroblast cell media: Remove 55ml of DMEM:F12 medium (Life Technologies, 
Cat. No. 31331-028) from the bottle. Add 50ml of fetal bovine serum (Life 
Technologies, Cat. No 16000-044) and 5ml penicillin/streptomycin (Life 
Technologies Cat. No. 15140-122). Store at 4oC for up to 4 weeks. 
3. Sodium butyrate (Tocris, Cat. No. 3850). Dilute 50mg in 4.54ml in H2O and store 
aliquots at -20oC. Dilute 1:200 in cell culture medium for a final concentration of 
0.5mM. 
4. DPBS, no calcium no magnesium (Life Technologies, Cat. No. 14190-94) 
5. TrypLE™ Select Solution (Life Technologies, Cat. No, 12563-011). 
6. Cell freezing solution: For 50ml of solution combine 30ml DMEM (Life 
Technologies, Cat. No 41966-029) with 15ml fetal bovine serum and 5ml DMSO 
(Life Technologies D12345). Store at 4oC. 
7. Gelatin-coated plates. Add 1g gelatin (Sigma-Aldrich, Cat. No. G9136) to 500ml 
of ddH2O. Autoclave the solution to dissolve and sterilise. Add 5ml of the solution 
to a 10cm2 tissue culture treated dish in the laminar flow hood. Incubate at room 
temperature for an hour. Remove the excess gelatin prior to use. Plates can be 
wrapped in parafilm and stored at 4oC for up to a week. 
8. Amaxa™ Cell Line Nucleofector® Kit R (Lonza, Cat. No. VCA-1001. 
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9. Yamanaka episomal reprogramming plasmids (Okita et al. 2011 - Addgene, 
pCXLE-hOCT3/4-shp53-F (Cat. No.27077); pCXLE-hUL (Cat. No. 27080); 
pCXLE-hSK (Cat. No. 270778); pCXLE-GFP (Cat. No. 27082)).  
10. HESC qualified Matrigel-coated plates: All tissue cultureware, plastics and media 
should be ice-cold to prevent gelling of the Matrigel. Defrost the BD Matrigel™ 
hESC-qualified matrix solution (BD Biosciences, Cat. No. 354277) overnight in 
an ice bucket within a fridge). Dilute 1:1 with DMEM, prepare 1ml aliquots in 
1.5ml microcentrifuge tubes and store at -20oC. Thaw aliquots overnight as 
described above and dilute in DMEM to the final ratio suggested according 
manufacturers certificate of analysis. Coat tissue culture plastic (1ml/well of a 6-
well plate, 3ml/T25 flask) and incubate at room temperature for at least an hour. 
Aspirate off excess Matrigel immediately prior to use. 
11. mTeSR™1 Media Complete Kit (Stem Cell Technologies, Cat. No. 05850). 
Prepare according to the manufacturers instructions. 
12. Stainalive™ Tra-1-60 Antibody (DyLight™ 488), mouse anti-human 
(STEMGENT, Cat. No.09-0068). 
13. Stainalive™ Tra-1-81 Antibody (DyLight™ 488), mouse anti-human 
(STEMGENT, Cat, No,  09-0069). 
14. iPSC-RPE differentiation media: All components are supplied from Life 
Technologies. Remove 111.2 ml of media from a bottle of Knockout™ DMEM 
(Cat. No. 10829-018) and add 100ml of KnockOut™ Serum Replacement (Cat. 
No. 10828010), 5ml of 200mM L-Glutamine (Cat. No. 25030-081), 5ml of 100x 
MEM Non-essential amino acids (Cat. No. 11140-035), 909µl of 55mM β-
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mercaptoethanol (31350-010) and 300µl of 50mg/ml Gentamicin (Cat. No. 
15750-037). Store at 4oC for up to 4 weeks. 
15. Accutase® Solution (Sigma-Aldrich, A6964). 
16. BD Matrigel Growth Factor reduced (GFR) matrix (BD Biosciences, Cat. No. 
356230). Thaw, dilute 1:1 with DMEM, aliquot and store as described above. 
Dilute 1:15 with DMEM to coat plates for a final dilution of 1:30, incubate at 37oC 
for at least 2 hours, place at room temperature for 1 hour and aspirate excess 
Matrigel immediately prior to use. 
17. 30% sucrose cryopreservation solution: Dissolve 30g of sucrose (Sigma, Cat. 
No.S0389) in 0.01M PBS (Sigma, Cat. No. P4417) to a final volume of 100ml. 
18. OCT embedding compound (CellPath, Cat. No. KMA-0100-00A).  
19. Immunocytochemistry cell permeabilisation solution: For a 50ml solution, dilute 
1.5ml of 10% Triton-X solution (Sigma-Aldrich, Cat. No.93443) in 0.01M PBS. 
20. Immunocytochemistry blocking solution: Add 0.5ml of normal donkey serum 
(Jackson ImmunoResearch Laboratories Ltd.) to 0.3g of Bovine serum albumin 
and make up to 10ml with PBS. 
21. RPE specific antibodies: Pmel17 Mouse monoclonal antibody (Dako, Cat. No. 
M0634, 1:500 final dilution), MerTK Rabbit monoclonal antibody (Abcam, Cat. 
No. ab52968, 1:50 final dilution), Bestrophin Mouse monoclonal antibody  
(Abcam, Cat. No. a2182, 1:1000 final dilution). 
22. Secondary antibodies; Donkey Anti-mouse IgG Alexa Fluor® 488 (Abcam, Cat. 








1. 7ml Bijou tube. 
2. Conical tubes (15ml and 50ml). 
3. 1.5ml microcentrifuge tube. 
4. Cryovial cryogenic preservation tubes. 
5. 6-well tissue culture-treated plate. 
6. 10 cm2 tissue culture-treated plastic dish. 
7. 25 cm2 (T25) tissue culture-treated plastic flask. 
8. 160 cm2 (T60) tissue culture-treated plastic flask. 
9. Extended fine tip Pasteur pipette (Alpha Labs, Cat. No. LW4636). 
10. Sterile serological pipette (5ml, 10ml, 25ml). 
11. 40µM Cell Strainer (Corning, Cat. No. 352340). 
12. 22 x 22mm glass cover slip (VWR, Cat. No. 631-0124). Sterilise the coverslips 
overnight by immersing in 100% ethanol. Allow to dry thoroughly before placing 
on cells. 
13. 22 x 50 mm glass coverslip (VWR, Cat. No. 631-0094) 
14. Sterile cell scraper (Greiner Bio-one, Cat. No. 541070). 
15. 11mm Crescent blade microknife (Interfocus, Cat. No 10317-14). 





1. Tissue culture incubator (humidified to 95% with 5% CO2 maintained at 37oC). 
2. Laminar flow hood (Class I and II). 
3. Centrifuge. 
4. Media Aspirator  
5. Sterile dissection forceps. 
6. Sterile scalpel blades. 
7. Dissection teasing needle. 
8. Water bath. 
9. Inverted Microscope with LCD screen (2, 4, 10 and 20x objectives) contained 
inside a laminar flow hood. 
10. Cell counter (automated or haemocytometer). 
11. CoolCell SV2 cell freezing container (Biocision Cat. No. BCS-172). 
12. Liquid nitrogen storage tank with cryovial storage racking. 
13. Amaxa Nucleofector device. 
3. Methods 
3.1 Generation of fibroblast cells from a patient dermal skin biopsy 
1. A 5-mm skin biopsy should be obtained from a patient with informed consent 
under aseptic conditions by a trained physician. The protocol should be approved 
by the appropriate research ethics committee and review board.  
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2. Collect the biopsy and transfer to a sterile 7ml Bijou tube containing fibroblast cell 
media and transport on ice to the laboratory. 
3. Remove the biopsy sample from the tube using sterile forceps and place into a 
10cm2 sterile culture dish containing DPBS to wash the sample. 
4. Remove the epidermal layer of the skin using a sterile scalpel blade. 
5. Place the biopsy into a fresh 10cm2 dish and dissect the biopsy into small pieces 
(approx. 1mm) using sterile scalpel blades. 
6. Transfer the biopsy fragments to two wells of a 6-well tissue culture-treated plate 
and overlay with a sterile 22 x 22mm glass coverslip. 
7. Carefully add 500µl of fibroblast media to the well so that sufficient media is 
drawn underneath the coverslip. 
8. Culture the sample overnight in a humidified incubator at 37oC, 5% CO2. 
9. The following day add 1.5ml of fibroblast media and culture the tissue for 2-3 
weeks to permit primary fibroblast cell emergence (Figure 1A).  
10. When sufficient fibroblast cell outgrowth has occurred (approx. 70% confluence) 
the cells are ready to be passaged. 
11. Aspirate the media and transfer the coverslip to a fresh well, inverting the 
coverslip so that the side which has been in contact with cells is uppermost (see 
Note 1). 
12. Wash the coverslip and cells with sterile DPBS and add 500µl of TrypLE™ Select 
solution to each well. Incubate at room temperature until cells have detached 
(approx. 10 min). 
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13. Add 2ml of fibroblast medium to each well. Collect the media and pool in a 15ml 
conical tube. Remove clumps of tissue by placing the media through a cell 
strainer (see Note 2). 
14. Resuspend the cells in an appropriate volume of media (2ml per well of a 6-well 
plate or 6ml per T25) and passage at a ratio of 1:3 (see Note 3).  
15. Replace the fibroblast medium twice weekly and passage the cells using 
TrypLE™ solution as described above when the cells reach approx. 75% 
confluency, maintaining a 1:3 split ratio (see Note 4). 
16. Patient fibroblast cells can be cryopreserved long-term in liquid nitrogen. 
Dissociate cells using TrypLE™ solution as above and resuspend cells in 
fibroblast media. Centrifuge the cells at 250 x g for 5 min and aspirate the 
supernatant leaving a small miniscus of media (approx. 50µl) in which to 
resuspend the cells. Add 1ml of Cell Freezing solution and ensure cells are fully 
dispersed. Aliquot the cells into cryo-preservation vials (cells from 1 well of a 6-
well plate aliquoted into one vial, from a T25 into three vials). Place the cryovials 
inside a CoolCell SV2 controlled rate freezing container and freeze overnight in a 
-80oC freezer. Vials should be transferred into liquid nitrogen storage the 
following day. 
17. Cells can be recovered from cryopreservation prior to reprogramming. Warm the 
vial in a 37oC  water bath until most of the tube has thawed. Wipe the tube with 
70% alcohol before adding 1ml of pre-warmed fibroblast cell media. Carefully 
transfer the contents of the cryovial to a 15ml conical tube containing 5ml of 
warm fibroblast media. Centrifuge the cells for 3 min at 250 x g  and aspirate the 
14	  
	  
supernatant. Resuspend the cells in 2ml of fibroblast media and transfer to a well 
of a 6-well plate. The cells should be cultured as described above. 
 
3.2 Reprogramming of patient fibroblast cells into induced pluripotent stem cell 
lines 
1. On the day of the transfection prepare gelatin-coated 10cm2 culture dishes. 
2. Pre-warm the Nucleofector reagent and DPBS to room temperature. Warm the 
fibroblast media to 37oC . 
3. Dissociate fibroblast cells from a T160 using TrypLE™ solution as described 
above (see Note 5).  
4.  Resuspend in the cells in 1ml of DPBS and centrifuge at 250 x g for 3 min. 
5. Count cells using an automated cell counter or haemocytometer.  
6. Aliquot 1x106 cells into a sterile 1.5ml microcentrifuge tube, centrifuge at 250 x g 
for 3 min. Remove the supernatant and resuspend the cells in 100µl of 
Nucleofector solution (prepared according to the manufacturers instructions). 
Add 1 µg of each of the three Yamanaka episomal reprogramming plasmids 
(pCXLE-hUL, pCXLE-hOCT3/4-shp53-F and pCXLE-hSK). A control transfection 
reaction to examine transfection efficiency can be prepared by adding 3µg of 
pCXLE-GFP to cells to electroporate in parallel with the reprogramming cells. 
7. Pipette the reaction gently to mix then transfer the reaction into an Amaxa 
electroporation cuvette ensuring minimal bubble formation. 




9. Remove the cuvette from the device and add 1ml of warm fibroblast cell medium. 
10. Remove the gelatin solution from the 10 cm2 plates and add 8 ml of warmed 
MEF media  
11. Transfer the cell suspension from the cuvette into the prepared 10cm2 dish. 
12. Add an additional 1ml of medium to the cuvette to collect any remaining cells and 
transfer to the 10cm2 dish. 
13. Incubate the cells overnight at 37ºC and 5% CO2 
14. Over the following six days replace the media daily with 10 ml fibroblast media 
containing 0.5mM Sodium Butyrate (see Note 6). 
15. Prepare HESC qualified Matrigel-coated plates on the 7th day following the 
transfection.  
16. Dissociate the transfected patient fibroblast cells using TrypLE™ solution as 
previously described and resuspend in 5ml of fibroblast media.  
17. Count the cells and plate at a concentration of 2 x 105 cells/well of the coated 6-
well plate in a final volume of 2 ml media per well. Culture the cells the overnight 
37ºC and 5% CO2. 
18.  Remove the medium from each well on the following day and replace with 2ml of 
mTeSR™1 medium supplemented with 0.5mM sodium butyrate. The cell media 
should be replaced daily, supplementing with sodium butyrate for the first five 
days only.  
19. The appearance of pluripotent colonies in reprogrammed cultures can vary 
between patients however ESC-like colonies should begin to emerge within three 
weeks of the initial transfection. Under a x2 microscope objective the cells grow 
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within tightly compacted colonies that have a phase positive appearance with 
defined edges. (Figure 1B) Cells have a high nucleus:cytoplasm ratio. 
3.3 Isolation of clonal iPSC colonies  
1. Pluripotent colonies can also be identified using StainAlive™ stem cell antibodies 
for the stem cell surface proteins Tra-1-60 and Tra-1-81. Aspirate the medium 
from the cells and add fresh mTeSR™1 medium containing 3µg/ml StainAlive™ 
antibody. Incubate the cells at 37oC, 5% CO2 for 30 min. Remove the medium, 
and wash twice with cell medium. Add fresh mTeSR™1 and image the cells 
using a fluorescent microscope (Figure 1C, see Note 7). 
2. On the day of picking, prepare the required number of 6-well plates by coating 
wells with HESC-qualified Matrigel Basement membrane matrix (1ml of solution 
per well). For clonal iPSC lines prepare 1 well per colony. 
3. Transfer the plate to laminar flow hood containing an EVOS XL or equivalent 
LCD display microscope. 
4. To pick iPSCs, gently cut the iPSC colony by scoring criss-cross over the colony 
with the edge of a fine tip plastic Pasteur pipette. Use the tip of the pipette to 
gently lift the colony fragments away from the surrounding cells (see Note 8). 
Collect the free-floating colony fragments using the Pasteur pipette and transfer 
to a well of the Matrigel coated 6-well plate and add 1ml of medium.  
5. Replace the medium on the original plate containing the reprogrammed cells with 




6. Incubate the cells at 37oC, 5% CO2, taking care not to disturb the plate for 48 
hours in order to permit colony attachment. Following this cells should be fed 
daily with fresh mTeSR™1 medium. Pluripotency can be confirmed by 
immunostaining for pluripotent stem cell markers e.g. Oct4 and Tra-1-81 (Figure 
1D). 
7. iPSC colonies will be ready to passage within 4-7 days. To maintain and expand 
the iPSC line it is important to removal any differentiated cells prior to passaging; 
this can be achieved by scrapping across any areas of differentiation with the tip 
of a Pasteur pipette to detach cells. The well should then be washed with media 
before adding fresh mTeSR™1 medium prior to passaging. Fragment and detach 
the cells by scoring across the clonal colonies within a well and as described 
above (Figure 1E) and replate onto HESC qualified Matrigel -coated tissue 
culture plastic at a split ration of 1:3-1:6. 
 
3.4 Spontaneous differentiation of patient iPSCs into RPE 
1. Passage the iPSCs onto Growth Factor reduced Matrigel-coated plates or flasks 
as described above using mTeSR™1 medium, incubate the cells at 37oC, 5% 
CO2.. 
2. Replace the medium daily with mTeSR™1 until the individual iPSC colonies 
merge and become confluent over the dish/flask; this will occur approximately 8-
10 days post-seeding. 
3. Once cells have become confluent, replace the medium with a 1:1 mix of 
mTeSR™1:iPSC-RPE Differentiation medium.  
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4. The following day replace the medium with Differentiation medium only and 
culture the cells at 37oC, 5% CO2. From this point change the media twice 
weekly.  
5. Within a 4-6 week period, pigmented foci of retinal pigment epithelial cells, which 
are detectable by eye, should begin to appear within the cultures (Figure 1F). 
 
3.5 Isolation of pigmented foci from iPSC cultures and culture as a monolayer. 
1. Once pigmented foci have reached a sufficient size (>1mm diameter) dissect 
around the foci using a crescent blade. Place the foci into a fresh dish containing 
differentiation medium and carefully remove any non-pigmented tissue using 
sterile forceps and scalpel blades. 
2. Place the pigmented foci into a 15ml conical tube containing Accutase® solution 
and incubate at 37oC for 2-3 hours to dissociate cells. 
3. Pellet the cells by centrifugation at 250 x g for 3 mins and resuspend in 
differentiation medium. 
4. Pass the cells through a 40µm cell strainer to create a single cell suspension of 
retinal pigment epithelial cells. 
5. Count the cells using a haemocytometer 
6. Seed out the pigmented cells in differentiation medium at a minimum density of 
50,000 cells/cm2 on Growth factor reduced Matrigel-coated tissue culture plastic 
dishes. Incubate cells at 37oC, 5% CO2. 
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7. The media should be replaced with differentiation media twice weekly for 
approximately 6 weeks when a pigmented monolayer of cells forms (see Note 9).  
8. iPSC-derived RPE can be maintained in culture for several months to permit 
further maturation of the cell monolayer (see Note 10).  
 
3.6 Immunocytochemical staining of iPSC-derived RPE 
1. Remove the medium from the cells and wash twice with PBS.  
2. Fix the cells in 4% paraformaldehyde for in 0.01M phosphate buffer for 30 min at 
4oC . Wash twice with PBS. 
3. Using a cell scraper, slowly but firmly scrape off the RPE cells from the dish in 
one sweep, so that an intact sheet of cells is lifted. 
4. Carefully transfer the sheet to a bijou tube containing 30% sucrose using a 
teasing needle. Cryopreserve the sheet overnight at 4oC. 
5. The following day cut the RPE sheet into smaller pieces (approx. 1 cm2) for 
embedding. Fill a Cryomold with OCT compound being careful to exclude large 
air bubbles. Transfer the sheets into the OCT cryomolds and gently orientate the 
sheet into a vertical, on-edge position, using teasing needles.  
6. Place the bottom of the cryomold into a dry ice/acetone slurry bath and slowly 
freeze the block, ensuring the sheet maintains its vertical orientation. 
7. Store the blocks at -80oC. 
8. Section the tissue at 14µm on a cryostat and collect tissue sections on warm 
Superfrost® Plus slides. 
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9. Air dry the sections and use immediately or store at -80oC   
10. Permeabilise the tissue in 0.3% triton in PBS for 10min at 4oC . 
11. Remove the permeabilisation solution and incubate in blocking solution for a 
minimum of 30 mins. 
12. Place the slides inside an immunostaining moisture chamber, add RPE specific 
antibodies diluted in blocking solution to the sections and incubate at 4oC 
overnight. 
13. The following day wash the slides five times in PBS. 
14. Pipette the secondary antibodies diluted in blocking solution onto the sections 
and incubate for 1 hour inside a moisture chamber. 
15. Wash the slides five times in PBS 
16. Mount the cells by adding a drop of VECTASHIELD anti-fade mounting medium 
with DAPI over the tissue sections. Cover with a clean 22 x 50mm coverslip and 
seal with nail polish. 
3.7 Characterisation of the patient iPSC-derived RPE  
1. iPSC-RPE cells should be characterised to ensure their similarity to human RPE. 
iPSC-derived RPE cells can be examined initially by their morphological 
appearance. By eye, an even layer of brown/black cells should be visible on the 
tissue culture plastic (Figure 2A). The RPE form a monolayer of hexagonal cells 
arranged in a regular pattern (cobblestone-like appearance Figure 2B), are highly 
pigmented and appear brown/black under a standard microscope (Figure 2C). 
2. The intricate ultrastructure of the RPE cell can be analysed by electron 
microscopy (Figure 2D). RPE cells are highly polarised with prominent microvilli 
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and coated pits apparent on the apical surface, densely packed melanosomes 
within the apical cytoplasm and a basal nucleus. The RPE possess cell-cell 
adhesion structures including adherins junctions, tight junctions and 
desmosomes, and secrete their own basement lamina. 
3. Gene and protein expression can be examined for a panel of RPE markers 
(Table 1) using RT-PCR, immunostaining (see Note 11) and Western blot. RPE 
cell markers should be expressed in the correct cellular compartment. For 
example, Pmel17 is observed with punctate staining of the cytoplasm (Figure 
2E), MerTK should be expressed on the apical surface, whilst Bestrophin should 
be localised basolaterally (Figure 2F). 
4. RPE cells secrete a number of factors crucial for the survival and maintenance of 
photoreceptor cells, including Vasoactive Endothelial Growth Factor (VEGF) and 
Pigment epithelium-derived growth factor (PEDF). To analyse secretion of these 
factors iPSC-RPE should be grown on permeable culture membrane inserts. 
Apical and basal media can then be collected for cells and growth factor 
secretion measured using an ELISA kit.  
5. The RPE is a tight epithelium and is a component of the blood:retina barrier 
separating the retina from the choriocapillaris in vivo. The barrier function of 
iPSC-RPE cells can be assessed by measuring the transepithelial resistance. 
iPSC-RPE cells should be seeded onto permeable culture membrane insert and 
development of a functional barrier measured weekly over the course of RPE cell 
maturation using an epithelial voltohmmeter. 
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6. An important function of the RPE in the eye is the phagocytosis of the outer 
segment debris shed daily by the retinal photoreceptor cells. Functional 
phagocytosis can be examined in patient iPSC-RPE by exposing cells to 
fluorescently labelled photoreceptor outer segments isolated from porcine, 
bovine or ovine eyes. Alternatively, an isolated sheet of retina can be co-cultured 
above the RPE monolayer; RPE cells should then be assessed for ingestion of 
rhodopsin positive material by immunostaining. 
7. The RPE cell is vital for the recycling of retinoids in the visual cycle. In the 
photoreceptor cells the detection of light results in the isomerisation of the 11-cis-
retinal chromophore into all-trans-retinal, after further reduction the by-product of 
the visual cycle is released from the photoreceptor cell as all-trans-retinol. The 
RPE is responsible for the recycling of all-trans-retinol into 11-cis-retinal, which 
can then be transported back to the photoreceptor cells to form a new light-
absorbing photopigment molecule. Retinol derivatives of the visual cycle can be 
measured in cell lysates and cell media by High performance Liquid 
Chromatography (HPLC) or Liquid Chromatography-Mass Spectrometry (LC-
MS). 
8. The functional properties of iPSC-RPE cells can be assessed by transplantion of 
cells into the subretinal space of a retinal degenerate animal e.g. the Royal 
College of Surgeons (RCS) rat. Preservation of visual responses in these 





4. Notes  
1. Patient fibroblast cells can grow on the underside of the coverslip, these can 
easily be collected for alongside those on the plate for expansion. 
2. Any clumps of tissue from the patient skin biopsy can be reseeded onto fresh 
tissue culture plates as described above for further cell growth if required. 
3. Cells from a single well of a 6-well plate can be passaged into one T25 flask for 
expansion. With fibroblast cells it is important not to split for passage at a high 
ratio (>1:3) as the seeding density will be too low for the cells to survive. 
4. For reprogramming 1x106 fibroblast cells are required. A sufficient number of 
fibroblast cells can be achieved by expanding the cells and preparing a culture 
for the reprogramming in a T160 flask. 
5. For reprogramming cells should be at low passage (<p15) and still be in a 
proliferative phase, approximately two to three days following passage. 
6. To establish the efficiency of transformation examine the ratio of GFP 
expressing:non expressing cells on the control GFP transfected plates the day 
after electroporation. 
7. For ease of picking, the position of Stainalive™ verified pluripotent colonies can 
be marked on the underside of the plate using an objective stamp on the 
fluorescent microscope. 
8. When picking the colonies for the first time it is important to avoid disturbing any 
untransformed fibroblast cells surrounding each colony as these will be carried 
over in the sub-culture. 
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9. The iPSC-derived retinal pigment epithelial cells will initially de-pigment after 
passage, undergoing an EMT-like transformation, re-pigmentation and 
development of the epithelial cell morphology will occur over the six week culture 
period. 
10. iPSC-RPE derived cells can be expanded for a limited number of passages by 
dissociation using Accutase® solution. It is not advisable to continue passage of 
cells beyond p4 as the EMT phenotype prevails and cells fail to re-establish the 
RPE cell morphology. 
11. Immunostaining of iPSC-derived RPE cells can be masked due to the high levels 
of pigmentation in cells. We recommend using the protocol described in section 
3.7 to prepare cell sections for staining. 
 
5. Potential uses of iPSC-derived RPE 
There has been considerable success in generating human RPE in vitro from a number 
of human pluripotent stem cell sources including HESC (Klimanskaya et al. 2004, 
Vugler et al. 2008) and iPSC (Carr et al. 2009B; Vaajasaari et al. 2011; Kokkinaki et al. 
2011).  As a single layer of cells responsible for a number of eye diseases, the RPE is 
an ideal target for regenerative medicine, using stem cell derived RPE as a potential 
clinical source of replacement tissue. HESC-derived RPE are currently being assessed 
as a treatment for RPE-based diseases such as AMD and Stargardt’s macular 
dystrophy (Schwartz et al. 2012) and in other clinical trials worldwide. More recently, as 
part of a first-in-human iPSC clinical study, autologous iPSC-derived RPE have been 
made from, and transplanted back into a patient with AMD in Japan. However, the long-
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term success of these transplants the eye has yet to be evaluated. iPSC-derived RPE 
cells also offer a powerful new source of tissue for the modelling of RPE disorders, 
replacing animal models as a disease-in-a-dish tool to examine the development and 
pathogenesis of inherited and degenerative RPE disease [Park et al. 2008]. As patient 
iPSC-derived RPE also contain the genetic background responsible for RPE disease, 
the cells will also be a viable tissue source for investigating potential therapeutics in 
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Figure 1. Production of iPSC-RPE from a patient skin biopsy A) Fibroblast 
outgrowth from a skin biopsy. B) Emergence of iPSC colonies in reprogrammed cultures 
C) stained with Stainalive™ Tra-1-60 antibody. D) Oct4 (green) and Tra-1-81 staining of 
iPSCs. E) Dissection of iPSC colony for clonal expansion. F) Appearance of pigmented 





Figure 2 Characterisation of patient iPSC-derived RPE. A) Flask containing purified 
RPE. B) Cobblestone-morphology of RPE monolayer. RPE cells are highly polarised 
epithelial cells with C) a basal nucleus (blue) and are packed with melanosomes (Black 
granules). D) Electron microscopy of the RPE cell ultrastructure. Immunostaining of 
cells with E) the pre-melanosome marker Pmel17 (red) and F) apical expression of 
MerTK (green) and basolateral localisation of Best1 (red). 
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Table 1. Commonly used markers to identify retinal pigment epithelial cells. (abbreviations: retinal pigment 
epithelium (RPE), retinitis pigmentosa (RP), Leber’s congenital amaurosis (LCA), retinal dystrophy (RD), rod-cone 
dystrophy (RCD), Fundus albipunctatus (FA), photoreceptor outer segments (POS), age-related macular degeneration 
(AMD).  
Gene  Description Role Notes  Reference 
RPE65 RPE specific 65kDA Visual Cycle Mutations lead to RP or LCA Wright et al (2015), den Hollander 
(2008) 
LRAT Lecithin retinol 
acyltransferase 
Visual Cycle Mutations lead to early onset RD Dev Borman (2012), den Hollander 
(2008) 
RLBP1 Retinaldehyde binding 
protein 1 
Visual Cycle Mutations lead to severe RCD, FA Maw (1997), Eichers (2002) 
FAK Focal adhesion kinase Phagocytosis Cell adhesion and motility Finneman (2003) 
MerTK Mer tyrosine protein kinase Phagocytosis Mutations leads to RP den Hollander (2008) 
ITGAV Integrin alpha 5 Phagocytosis Extracellular interactions with POS Finneman (1997) 
ITGBV Integrin beta Phagocytosis Extracellular interactions with POS Finneman (1997) 
CD36 Cluster of differntiation 36 Phagocytosis Extracellular interactions with POS Sun (2006) 
CD81 Cluster of differntiation 81 Phagocytosis Extracellular interactions with POS Chang and Finneman (2007) 
CTSD Cathespin D Phagocytosis Lysosomal protease – degrades 
internalised POS 
Bosch (1993) 
GAS6 Growth arrest specific 6 Phagocytosis MerTK interactions Hall (2001, 2005) 
MFGE8 Milk fat globule EGF factor 
8 
Phagocytosis Interacts with integrins Nadrot (2007) 
PROS1 Protein S Phagocytosis Interacts with MeRTK  
BEST1 Bestrophin 1 Ion transport Expressed basolaterally – implicated in 
Best’s disease 
Marmorstein (2000) 
ATP1A Na+/K+ ATPase Ion Transport Expressed apically Hu and Bok (2001) 
TYR Tyrosinase Melanogenesis Oxidase Murisier and Beerman (2006) 
PMEL17 Premelanosome protein 17 Melanogenesis Biogenesis of pre-melanosomes Vugler (2008) 
MITF Micropthalmia associated 
transcription factor 
RPE development Regulates transcription of RPE specific 
genes – associated with microphthalmia 
and anophthalmia 
Martinez-Morales (2004) 
OTX2 Orthodenticle homolog 2 RPE development Expressed in developing head and RPE 
- eoRD 
Martinez-Morales (2004) 
PAX6 Paired box protein 6 Transcription 
Factor 
Early eye field marker – associated with 
eye defects 
Martinez-Morales (2004) 
COL4A1 Collagen IV Extracellular matrix Secreted component of RPE basement 
membrane 
Campochiaro (1986) 
PEDF Pigment epithelium derived 
factor 
Growth Factor Anti-angiogenic factor  Dawson (1999) 
VEGF Vascular epithelium growth 
factor 
Growth Factor Pro-angiogenic factor - associated with 
wet AMD 
Witmer (2003) 
KRT8 Keratin 8  Marker of proliferative RPE Vugler (2008) 
